title: [Intrapericardial lung cancer metastases: Is a curative approach feasible?].
abstract: BACKGROUND
  Lung cancer metastases are classified M1a and M1b. Studies on patients with pleural invasion graded M1a have demonstrated the possibility of prolonged survival following multimodality treatment, but this has not been reported for M1a pericardial involvement.
  
  
  METHODS
  A 59-year-old man underwent lung surgery for a poorly differentiated adenocarcinoma TTF1+ with K-ras mutation. He was staged as pT4N0 because of a nodule in another ipsilateral lobe. A pericardial effusion with imminent tamponade occurred during the postoperative course necessitating drainage leading to the discovery of pericardial metastases and restaging as pT4N0M1a. Adjuvant treatment was performed and the patient remains alive and disease free 3 years later.
  
  
  CONCLUSIONS
  Management of pericardial M1a might be refined as has been the case in pleural M1a disease. Biological data might allow more precise classification and treatment. N0-N1 and non-T3-T4 by invasion patients might in selected cases benefit from surgery included as part of multimodal therapy.
authors.affiliation: Service de chirurgie thoracique, hôpital européen Georges-Pompidou, université Paris Descartes, 20-40, rue Leblanc, 75015 Paris, France. Electronic address: marc.riquet@egp.aphp.fr.
authors.forename: M
authors.initials: M
authors.lastname: Riquet
authors.affiliation: Service de chirurgie thoracique, hôpital européen Georges-Pompidou, université Paris Descartes, 20-40, rue Leblanc, 75015 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Rivera
authors.affiliation: Service de chirurgie thoracique, hôpital européen Georges-Pompidou, université Paris Descartes, 20-40, rue Leblanc, 75015 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Mordant
authors.affiliation: Service d'oncologie médicale, hôpital européen Georges-Pompidou, université Paris Descartes, 75015 Paris, France.
authors.forename: É
authors.initials: É
authors.lastname: Fabre
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary* / Q000628:therapy*; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006338:Heart Neoplasms / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed; D010496:Pericardium / Q000473:pathology*; D011013:Pneumonectomy; D012074:Remission Induction
chemical_list: D005971:Glutamates; D000068437:Pemetrexed; D006147:Guanine; D016190:Carboplatin
keywords: Cancer du poumon; Chirurgie; Lung cancer; Molecular-targeted therapy; Métastases péricardiques; Pericardial metastasis; Surgery; Thérapie ciblée